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Abstract 
Purpose: To measure the arterial input function (AIF), an essential component of tracer kinetic 
analysis, in a population of patients using an optimized dynamic contrast-enhanced imaging 
sequence and to estimate inter- and intra-patient variability. From these data to extract a 
representative AIF that may be used for realistic simulation studies. 
Methods: Thirty-nine female patients were imaged on multiple visits before and during a 
course of neoadjuvant chemotherapy for breast cancer. A total of 97 T1-weighted dynamic 
contrast-enhanced studies were analyzed including bookend estimates of T1 and model-fitting 
to each individual AIF. Area under the curve and cardiac output were estimated from each first 
pass peak and these data were used to assess inter- and intra-patient variability of the AIF. 
Results: Inter-patient variability exceeded intra-patient variability of the AIF. There was no 
change in cardiac output as a function of MR visit (mean value 5.6 ± 1.1 L/min) but baseline 
blood T1 increased significantly following the start of chemotherapy (which was accompanied 
by a decrease in hematocrit). 
Conclusion: The AIF in an individual patient can be measured reproducibly but the variability 
of AIFs between patients suggests that use of a population AIF will decrease the precision of 
tracer kinetic analysis performed in cross-patient comparison studies. A representative AIF is 
presented that is typical of the population but retains the characteristics of an individually 
measured AIF. 
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Introduction 
Dynamic contrast-enhanced (DCE) MRI allows measurement of tissue hemodynamic 
characteristics by monitoring the delivery and distribution of an intravenously administered 
contrast agentWKURXJKLWVHIIHFWRQWKHWLVVXH¶VT1 relaxation time. Techniques for analyzing 
DCE data are undergoing continuous adaptation and are becoming a valuable tool in oncology 
(e.g. for diagnosis and monitoring of cancer) and other conditions (e.g. in the brain and kidneys) 
[1-3]. In particular, the introduction of quantitative assessment triggered a cascade of 
applications and had a significant effect on the acquisition techniques used in DCE-MRI [4]. 
MR signal intensity changes, due to the distribution of the contrast agent in the tissue, form 
temporal features that depend on the tissue pathophysiology, the imaging sequence used and 
the administration protocol and properties of the contrast agent. Quantitative analysis with 
tracer kinetic modelling allows the characterization of tissue microvasculature (e.g. tissue 
blood flow, blood volume fraction) and provides information on the exchange of contrast agent 
between vascular and interstitial compartments.  
In order to decouple the response of the tissue from the contrast agent administration protocol, 
tracer kinetic modelling requires the concentration of the contrast agent in the feeding arteries, 
also known as the arterial input function (AIF), to be determined. Ideally, the delivery of the 
contrast agent should be sampled from an artery that directly feeds the tissue of interest. 
Furthermore, the frequency with which the AIF is sampled has a significant impact on the 
accuracy and precision of the resulting parameter estimates and influences the choice of model 
[5,6]. The sampling rate is particularly important during the early phase following bolus 
administration, when the signal in blood exhibits large and rapid changes. These requirements 
impose certain spatio-temporal limitations on the acquisition protocol that are usually difficult 
to achieve. Furthermore, additional challenges such as partial volume, B1 inhomogeneity, 
incomplete spoiling and inflow effects may reduce the quality of the AIF measurement further 
and propagate as errors in subsequent tracer kinetic parameter estimates [7,8]. 
It is common that the acquired data do not allow an AIF to be measured reliably. In these cases, 
an AIF is either assumed from the time course of the mean blood plasma concentration from a 
number of relevant studies (a population AIF) or extracted from a functional form of AIF [9-
12]. One such approach, described by Parker et al. in 2006 [10], has proved to be very popular 
having been used numerous times for both simulation studies and data analysis. However, use 
of such approaches introduces limitations. The temporal details during the early bolus passes 
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may be distorted and individual variability (e.g. cardiac output, bolus injection duration and 
contrast agent dose) is lost [12]. Another proposed solution is the reference region approach 
[13,14], but this makes assumptions about the reference tissue; and the extracted AIF may 
feature different temporal characteristics than expected (i.e. lower and more dispersed first pass 
peak). Despite the alternative approaches, a reliably measured individual AIF is superior with 
respect to the accuracy of the parameter estimates [15-17]. 
It is essential to assess the repeatability of AIF measurement in order to understand the impact 
of using a population average AIF on subsequent tracer kinetic analysis. In this work we have 
used a high temporal resolution DCE-MRI acquisition protocol and measured AIFs from a 
population of thirty-nine patients with breast cancer undergoing neoadjuvant chemotherapy 
prior to surgical resection. The participants were scanned between 1 and 5 times before and 
during their therapy, resulting in a total of 97 datasets. Each individual AIF was fitted with a 
functional AIF form [12] and this was used to obtain a measurement of the area under the first 
pass peak from which we assessed intra- and inter-patient variability and hence examined the 
repeatability of AIF measurement in a population of patients. Finally, using the parameters 
estimated from the model, we present a representative AIF that retains the features of an 
individually measured AIF. 
Methods 
Patients 
Thirty-nine female patients (median age = 44, range = 25 ± 69 years) diagnosed with invasive 
breast cancer and due to undergo neoadjuvant chemotherapy prior to surgery were enrolled in 
this prospective study. The study was approved by a local research ethics committee and 
written informed consent was obtained from each patient. Blood samples, taken as part of 
normal standard of care, were used to measure the large vessel hematocrit (Hct) before each 
MRI scan. Patients with contraindications to MRI were excluded from the study.  
MR imaging 
All patients were scanned on a 1.5 T Aera MR scanner (Siemens, Erlangen, Germany), 
positioned head first prone, and data were acquired in the transverse plane using a bilateral 
breast coil. A flexible matrix coil was also positioned on the patients¶EDFNs to enhance the 
signal from the descending aorta. Before the dynamic acquisition, a 3D non-selective inversion 
recovery (IR) prepared spoiled gradient echo (FLASH) sequence (FOV: 340×340×180 mm, 
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matrix size: 128×128×36, IR-TR: 3000 ms, TR/TE: 2.8/0.93 ms, flip angle: 8°, GRAPPA 
parallel factor: 2, Tacq: 1 min 05 s per inversion time) was used at four inversion times (TI: 100, 
600, 1200 and 2800 ms) for T1 measurement. The accuracy of this approach was tested in a 
phantom study detailed in Supporting Information S1. The IR sequence was repeated 
immediately after the DCE-MRI experiment.  
The dynamic series consisted of 93 high temporal resolution volumes interleaved with 8 high 
spatial resolution volumes (the latter were not used in our analysis but are part of the standard 
breast protocol used in our clinic), a variation of the acquisition scheme proposed by Georgiou 
et al. [18]. For the high temporal resolution dynamic data, a T1-weighted 3D FLASH sequence 
(TR/TE: 2.37/0.73, FA: 25°, CAIPIRINHA parallel factor: 2×2, Tacq: 2 s) was employed with 
the same geometry used in the IR sequence. The volume selected encompassed both breasts, 
the heart, aortic arch and descending aorta (Figure 1). 
Contrast agent 
All patient studies followed the same contrast agent administration protocol. Gd-DOTA 
(Dotarem; Guerbet, Laboratories, Aulnays Sous Bois, France) was administered intravenously 
via the antecubital vein using an automated power injector (Spectris Solaris EP), at the 
beginning of the 11th dynamic volume (dose of 0.1 mmol/kg) followed by 20 ml of saline at a 
rate of 3 ml/s.  
Postprocessing 
Data were processed in PMI (Platform for Research in Medical Imaging, version 0.4 [19]) and 
Matlab (Mathworks, Nattick, MA, USA). For AIF extraction, regions of interest (ROIs) were 
drawn in the descending aorta and, for consistency across patients, were sampled in the same 
10 slices (starting from inferior slices, ROIs were drawn in the 5th to 14th slices). Fig. 1 
illustrates a representative example of the volume slab excited in our DCE-MRI experiment. 
The 3D ROIs were further trimmed to include only voxels that had a peak relative signal 
intensity change between the 50th and the 95th percentile of the signal change maxima [18]. 
These slices and percentiles were chosen empirically, to minimize inflow, section profile and 
partial volume artifacts. The median number of voxels included in the 3D ROIs for the AIF 
was 162 (range 87 ± 358).  
The ROIs extracted were used to sample the dynamic data to obtain the AIF time series and 
both sets of IR images to obtain a baseline and a post-contrast T1 measurement, by fitting the 
6 
 
 
IR-FLASH signal equation [20,21] to the measured signal intensities at the four inversion 
times. Using the pair of T1 estimates and the signal equation for a FLASH sequence [22], an 
iterative approach was followed to apply a bookend correction to the ǻR1 (T1 relaxation rate 
change) series, as described by Cron et al. [23]. To calculate the respective blood concentration 
time series for each patient a contrast agent relaxivity of 4.2 s-1 mM-1 was assumed [24]. As a 
last step, the extracted AIFs were time-shifted so that the contrast appeared at t = 0 and the data 
were truncated so that each AIF covered a period of approximately 4.5 minutes. 
For subsequent analysis we used a functional form to fit to each AIF, to allow more accurate 
interpolation and integration of the first pass peak. +RUVILHOG¶Vmodel [12] was used since it 
provides a description of contrast agent recirculation, dispersion and redistribution that is based 
on physiological factors and because it can be fitted to individual AIF data sets, as opposed to 
an experimentally derived functional form that is fitted to averaged data from a population of 
subjects [10]. In our implementation of the Horsfield model, three exponential decay terms 
were used to characterize extravasation and excretion, combined with repeated gamma variate 
functions to account for recirculation. The equation for the period between the start of the nth 
recirculation and the (n+1)th recirculation, is given by: 
ܥ௣ሺݐሻ ൌ ൥෍ ܣ௜݁ି௠೔௧ଷ௜ୀଵ ൩ ቎෍ ߛ൫ሺ݆ ൅  ?ሻߙ ൅ ݆ǡ ߚǡ ݐ െ ݆߬൯௡௝ୀ଴ ቏ ǡ ݊߬ ൏ ݐ ൏ ሺ݊ ൅  ?ሻ߬ 
ߛሺߙǡ ߚǡ ݐሻ ൌ  ௧ഀ௘ష೟ ഁൗఉሺഀశభሻ௰ሺఈାଵሻ ,      ݐ ൒  ?   (1) 
where Ai and mi are the amplitudes and time constants of the exponential terms, the coefficients 
Į and ȕ UHIOHFWWKHQXPEHURI³WKHRUHWLFDOPL[LQJFKDPEHUV´DQGWKHUDWLRRIWKHYROXPHRIWKH
mixing chambers to the volume flow rate, and Ĳ is the recirculation time. The gamma variate 
function takes the form given above for all t  0 and is 0 for all t < 0. 
Eqn. 1 was fitted to the individual AIFs using the Levenberg-Marquardt iterative least-squares 
optimization algorithm. Given the large number of fit parameters, we used multiple random 
initial estimates within a predefined range for each parameter. The first pass was isolated from 
Eqn. 1 and an analytical solution for the area under the first pass curve (AUC1st) in terms of the 
fitting parameters was derived (Eqn. 2) 
ܣܷܥଵ௦௧ ൌ  ? ஺೔ఉഀశభ ቀ݉௜ ൅  ?ߚൗ ቁିሺఈାଵሻଷ௜ୀଵ                           (2) 
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Furthermore, using indicator dilution principles [25] we generated an estimate of the SDWLHQW¶V
cardiac output (CO) from each AIF ܥܱ ൌ ܦ ܣܷܥଵ௦௧ൗ          (3) 
where D is the dose of injected contrast agent, estimated by multiplying the concentration of 
Gd-DOTA used (0.5 mmol/ml) by the volume of contrast agent administered.  
Repeatability Assessment 
To assess the repeatability of AIF measurement in the patient cohort, we examined the 
variability in pre-contrast T1, ܣܷܥଵ௦௧ and CO estimates. In addition, we assessed variability of 
Hct. These were first assessed for normality using the Shapiro-Wilk test and a Q²Q (quantile-
quantile) plot. One-way analysis of variance (ANOVA) for repeated measurements was used 
to test for any significant changes across MRI visits and to estimate inter- and intra-patient 
coefficients of variability (CV). To select a representative AIF we first fitted the population 
average AIF using Equation 1, and then identified the individual AIF whose first pass profile 
was closest to that of the population average AIF, using the least square differences of the two 
time series. The respective parameter estimates from the individual patient were used to 
generate a representative AIF. 
Results 
In this study we analyzed 97 datasets from thirty-nine patients who underwent a total of 146 
MR examinations. Datasets were excluded due to: missing back coil, motion-corrupted AIF, 
deviation from the standard injection protocol (e.g. manual injection or slower injection) or 
missing IR data. Figure 2a shows the population-averaged AIF from all available datasets. The 
discontinuities in this plot are due to the interleaved acquisition scheme used [18]. Furthermore, 
although the number of DCE volumes was fixed for all scans, some data appear in the gaps 
because of the effect of variable time shifts.  
Figure 2b demonstrates how +RUVILHOG¶V model is implemented, with each recirculation 
(illustrated with a different color) progressing with the amount of contrast agent remaining 
from the previous pass plus that which is recirculated. An example of the individual AIFs and 
associated fits are also shown in Figure 3 for a patient who underwent four MR examinations.  
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The resulting model parameters were used in Eqn. 2 to estimate AUC1st. Table 1 shows the 
estimates obtained for pre-contrast blood T1, Hct, AUC1st, and CO. Figure 4 demonstrates the 
variability of these estimates within and between visits. All data followed a normal distribution 
(p > 0.05, Shapiro-Wilk test) and the results of the ANOVA test (Table 2) suggest that there 
were no significant differences between visits for both AUC1st (p = 0.77) and CO (p = 0.70). 
There was a significant difference in the blood T1 estimates (p < 0.001) with a step increase 
between visit 1 (pre-chemotherapy) and visits 2, 3 and 4 (all during chemotherapy). Similarly, 
Hct showed a significant change across visits (p < 0.001), with a decrease seen at visits 3, 4 
and 5 compared to baseline.  
For both AUC1st and CO variability within patients (total mean squares, MS = 0.01 mMÂmin 
and 0.29 L/min, respectively) was lower than variability between patients (MS = 0.16 mMÂmin 
and 2.45 L/min, respectively). Similarly, the inter- and intra-patient CV were estimated to be 
21% and 11% for AUC1st, 17% and 11% for CO, 7.7% and 7.1% for Hct and 4.6% and 4.2% 
for T1. 
Figure 5 illustrates the representative AIF from this patient cohort plotted alongside the 
population AIF from  [10]. The fitted parameters are shown in Table 3 and an Excel file of the 
respective time series, at a high temporal resolution (0.1 s), is provided as Supporting 
Information S2. The AIF was measured following a bolus administration of 14.4 ml of Gd-
DOTA at 3 ml/s followed by 20 ml of saline, from a female patient, aged 59 years with an Hct 
of 0.35 and a mass of 72 kg. 
Discussion 
In 2006 Parker et al. published a population-averaged AIF [10] that has subsequently been used 
by numerous investigators for both simulations and data analysis. Since then, DCE-MRI 
acquisition has improved allowing many of the limitations of that study to be addressed. We 
measured an AIF in 97 separate MRI studies obtained from a population of 39 patients. Our 
AIF measurements were performed at a high sampling rate (2 s per acquisition compared with 
5 s previously [10]) using a flexible coil to enhance the signal from the descending aorta and 
to allow for a detailed characterization of the first pass and subsequent recirculations of the 
contrast agent bolus in the blood. Another strength of this protocol was the use of bookend IR 
T1 measurements, which have been shown to improve the accuracy with which contrast agent 
concentration is estimated [26].   
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In Figure 2 we show a plot of the population-average AIF from all studies alongside an example 
AIF from an individual study. It is clear that the detailed temporal characteristics of the second 
pass seen in the individual AIF are lost in the population average AIF. Moreover, the majority 
of the individual AIFs examined in this study were characterized by a third pass peak, which 
is smoothed over in the population-average AIF. Incomplete sampling of the early bolus passes 
has been shown to introduce significant errors and fit failures in quantitative tracer kinetic 
analysis of tissue curves [18]. The different characteristics of the individual and population-
average AIFs are likely the reason why 3DUNHU¶V population-average functional form failed to 
converge to satisfactory fits on individual AIFs [12]. 3DUNHU¶V model uses two Gaussians to 
account for the first pass and the second recirculation peak. +RUVILHOG¶VUHFLUFXODWLRQPRGHOLV
able to capture multiple passes despite having fewer fit parameters (9 versus 10 parameters).  
Using Eqn.3 we estimated AUC1st in order to examine the variability of the AIFs for this patient 
cohort. Within patients there were no significant differences in AUC1st between MRI visits. 
Furthermore, both MS and CV estimates for inter-patient variability were higher than for intra-
patient variability. The 21% inter-patient CV suggests that use of a population average AIF 
will introduce additional variability and thus potentially limit the sensitivity of quantitative 
analysis across patients. Using AUC1st we estimated CO, as described by Yang et al. [14]. The 
mean CO estimate was in good agreement with that measured in patients at rest and lying prone 
[27], providing indirect support for the accuracy of our measured AIFs. As noted by Yang, if 
the population-averaged AIF described by Parker is used to estimate CO, it results in an 
unrealistically high value (10.5 L/min) [14]. This may be due principally to under-sampling of 
the first pass leading to underestimation of AUC1st [14] but will also have been affected by B1 
and inflow artifacts. This suggests that XVHRI3DUNHU¶VSRSXODWLRQ$,)in quantitative analysis 
may introduce systematic overestimation of tracer kinetic model parameters.  
Our baseline blood T1 estimates match very well those recently reported in the literature at 1.5 
T. For example, Dabir et al. provided estimates of 1551 ± 115 ms and 1572 ± 111 ms for blood 
T1 from 102 healthy volunteers and 113 low-risk patients, respectively, of whom 51% were 
males [28]. Further studies in female subjects report blood T1 values of 1667 ± 77 ms (n = 20 
healthy females, [29]), 1664 ± 62 ms (n = 38 healthy females, [30]) and 1666 ± 77 ms (n = 65 
females with at least one risk factor for heart failure, [30]). A factor that affects blood T1 is Hct, 
which has been shown to account for the differences seen between female and male subjects; 
our patient cohort included female patients only and we saw a weak negative correlation 
between Hct and T1 (r = -0.27, p = 0.006). Chemotherapy can have an impact on Hct; there was 
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a significant decrease in Hct for visits 3, 4 and 5 and an increase in T1 for visits 2, 3 and 4 in 
comparison with visit 1 (p < 0.005).  
 
In this study we used an optimized acquisition protocol to measure the AIF in a group of 
patients with breast cancer undergoing neoadjuvant chemotherapy. Our aim was to reduce 
variations caused by experimental measurement errors to examine variations that are inherent 
to individual patients. To achieve this, we used the same dose of contrast agent for all patients 
and the administration protocol was fixed. Data were acquired at a temporal resolution that was 
appropriate to sample the early bolus passes of the AIF and the use of a flexible coil on the 
patient¶s back enhanced the SNR from the aorta. Measurement errors related to inflow effects 
[7] were addressed by careful placement of the imaging volume to encompass heart, aortic 
arch, a significant region of lung tissue as well as descending aorta which also helped to reduce 
partial volume artifacts - Parker et al. used only a single slice and included data from the iliac 
arteries [10]. We have used a T1 measurement technique based on a non-selective inversion 
recovery sequence, which is less prone to errors than a variable flip angle acquisition, and a 
bookend T1 method to improve the accuracy of estimates of contrast agent concentration 
[23,26]. The result is a series of AIFs with excellent intra-patient repeatability but that highlight 
larger inter-patient variability. We provide the parameters of a functional form of a 
representative AIF from the patient cohort that would be ideal for simulation studies or intra-
patient comparisons. For inter-patient comparisons reliable individual AIFs should be 
measured, where possible. If not, the use of a representative AIF may be necessary but is likely 
to decrease the precision of tracer kinetic analysis.  
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Figures 
 
Figure 1.  Example of the MRI volume slab acquired for the DCE data, which included the (i) 
heart, (ii) aortic arch, (iii) descending aorta and (iv) breasts. The image represents a maximum 
intensity projection in the sagittal plane. This was generated after subtracting the pre-contrast 
high spatial resolution volume from the first post-contrast high spatial resolution volume, and 
reconstructing the images in the sagittal plane. The dashed lines demonstrate the region where 
the AIF was sampled. 
 
 
Figure 2. (a) Average AIF with error bars (± one standard deviation) across 97 individual AIFs. 
Note that the gaps in the time series are due to the interleaved acquisition scheme and averaging 
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GDWDSRLQWVRQHDFKVLGHRIVXFFHVVLYHDFTXLVLWLRQEXUVWV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form fitted to an individual AIF. The black solid line indicates the fitted line through the data 
(asterisks). The colored data points indicate the recirculation phases of the contrast agent. 
 
 
Figure 3. Measured AIFs (asterisks) and individual fits (solid lines) from one patient over four 
MRI visits. The estimated CO was 4.56, 5.05, 6.02 and 4.98 L/min at visits 1 to 4 (patient age: 
39 years, weight: 63.5 kg at each visit, volume of Gd-DOTA administered: 12.7 ml at each 
visit). 
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Figure 4. Boxplots of AUC1st, CO and pre-contrast blood T1 as a function of MRI visit. The 
box represents the middle 50% of values for the visit, and the upper and lower whiskers the 
complete range. *** denotes a significant difference at the 95% significance level. 
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Figure 5. A representative AIF from this patient cohort (blue line) that was obtained from a 59 
year old female with a body weight of 72 kg, receiving a bolus of 14.4 ml of Gd-DOTA (dose 
of 0.1 mmol/kg) administered at a rate of 3 ml/s and followed by 20 ml of saline. The SDWLHQW¶V
Hct at the time of the scan was 0.35 and estimated CO from this AIF was 5.2 L/min. The 
population AIF of Parker et al. [10] is shown alongside for comparison (red line), and when 
converted to plasma concentration the representative AIF converges with the data presented by 
Weinmann et al [31] by ~10 mins post-injection. 
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Table 1. Blood T1, AUC1st and CO estimates for each MR visit. 
              
Parameters 
Visit 1 
baseline  
(n=29) 
Visit 2 
post-cycle 1 
(n=25) 
Visit 3 
post-cycle 3 
(n=20) 
Visit 4 
post-cycle 5 
(n=5) 
Visit 5 after 
chemotherapy 
(n=18) 
Overall 
(n=97) 
  DĞĂŶцʍ DĞĂŶцʍ DĞĂŶцʍ DĞĂŶцʍ DĞĂŶцʍ DĞĂŶцʍ 
Blood T1 (ms) 1626 ± 72 1718 ± 107 1716 ± 80 1782 ± 55 1696 ± 82 1689 ± 95 
Hematocrit 0.41 ± 0.02 0.39 ± 0.03 0.37 ± 0.03 0.35 ± 0.04 0.36 ± 0.02 0.38 ± 0.03 
AUC1st (mM.min) 1.28 ± 0.28 1.26 ± 0.32 1.28 ± 0.25 1.31 ± 0.23 1.29 ± 0.25 1.28 ± 0.27 
CO (L/min) 5.66 ± 0.93  5.68 ± 1.38 5.49 ± 1.01 5.67 ± 1.01 5.53 ± 1.13 5.61 ± 1.10 
 
Table 2. Results of the one-way ANOVA for repeated measures. 
 
df ± degrees of freedom, MS ± Mean Squares, SS ± sum of squares, * denotes significance at 95% level 
 
    AUC1st (mM.min) CO (L/min) T1 (ms) Hct 
Source df Partial SS MS  F p Partial SS MS  F p Partial SS MS  F p Partial SS MS  F p 
Patient ID 30 5.55 0.19    82.63 2.75    329466 10982    0.035 0.001    
MRI visit 4 0.05 0.01 0.46 0.77 1.17 0.29 0.55 0.7 126741 31685 5.86 0.001* 0.033 0.008 19.69 <0.001* 
 
  
   
  
   
  
        
  
Residual 62 1.58 0.03     32.79 0.53     335108 5405     0.026 0.000     
Total 96 7.15 0.07    116.08 1.21    859547 8954 
 
  0.100 0.001    
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Table 3. Parameter estimates for the functional form of the representative AIF.  
Parameter A1 m1 A2 m2 A3 m3 Į ȕ Ĳ 
Value 0.37 0.11 0.33 1.17 10.06 16.02 5.26 0.032 0.129 
Unit mM min-1 mM min-1 mM min-1 - min min 
 
 
 
Supporting Information S1. Details of a phantom experiment performed to test the accuracy of the 3D IR-FLASH sequence for blood T1 
measurement. 
Supporting Information Figure S1. Bland-Altman plot of the difference between 3D IR-FLASH estimates of T1 and IR-SE estimates of T1 
against IR-SE T1 in the HCMR phantom. Horizontal lines representing mean bias (bold) and ±95% confidence intervals (faint lines) are 
shown. 
Supporting Information S2. A spreadsheet containing data describing the representative AIF derived from this patient cohort. It was calculated 
using Eqn. 1 and the parameters listed in Table 3 which were estimated from a best-fit to data obtained from a 59 year old female with a body 
weight of 72 kg, receiving a bolus of 14.4 ml of Gd-DOTA (dose of 0.1 mmol/kg) administered at a rate of 3 ml/s and followed by 20 ml of saline. 
The SDWLHQW¶VHct at the time of the scan was 0.35 and estimated CO from this AIF was 5.2 L/min.  
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Supporting Information S1 ʹ  Details of a phantom experiment performed to test the accuracy 
of the 3D IR-FLASH sequence for blood T1 measurement. 
We imaged the Hypertrophic Cardiomyopathy Registry (HCMR) phantom and assessed gels 
with T1 values in the range 344 to 2211 ms (measured in the same session using a single 
slice IR-spin echo (SE) sequence with a TR of 10 s and 8 TI times: 100, 200, 400, 800, 1600, 
3200, 6400 & 9000 ms). Results using the 3D IR-FLASH sequence with the acquisition 
parameters detailed in the main manuscript (IR-TR: 3000 ms, TR/TE: 2.8/0.93 ms, flip angle: 
8°, GRAPPA parallel factor: 2, four inversion times: 100, 600, 1200 and 2800 ms) were 
excellent. The 3D IR-FLASH sequence produced results with a mean bias of -9 ms and 95% 
confidence intervals of -24 to +7 ms. 
 
 
 
Supporting Information Figure S1. Bland-Altman plot of the difference between 3D IR-FLASH 
estimates of T1 and IR-SE estimates of T1 against IR-SE T1 in the HCMR phantom. Horizontal 
lines representing mean bias (bold) and ±95% confidence intervals (faint lines) are shown. 
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